DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Other Events
Item 8.01 Other Events
On June 19, 2017, DURECT Corporation, a Delaware corporation
(DURECT), issued a press release announcing that the previously
announced development and collaboration agreement with Sandoz AG
(Sandoz) has cleared review under the Hart-Scott-Rodino (HSR)
Antitrust Improvements Act of 1976 and has become effective, and
that Sandoz has made the $20 million upfront payment associated
with the agreement. A copy of DURECTs press release is attached
as Exhibit 99.1 hereto and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
Press Release of DURECT Corporation dated June 19, 2017
DURECT CORP ExhibitEX-99.1 2 drrx-ex991_6.htm EX-99.1 drrx-ex991_6.htm Exhibit 99.1 DURECT’s Collaboration with Sandoz Clears HSR Review and is Effective CUPERTINO,…To view the full exhibit click
here About DURECT CORPORATION (NASDAQ:DRRX)
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.